Traversa Therapeutics Lands $5M In Second Round

La Jolla-based Travera Therapeutics, which is developing biopharmaceuticals based on RNA interference (RNAi) technology, said Thursday that it has raised $5M in a Series B financing round. The round was led by Morningside Venture Investments Ltd., and also included Mesa Verde Venture Partners and existing investors. The firm said the funding will go towards advancing its oncology drugs into clinical trials. The firm explained that the funding will provide it with two years of operating cash, and should take it to Phase I clinical trials. More information »